Contrast Media

Contrast media, also called contrast agents, are used to enhance the blood and perfusion in tissues. This includes iodine based contrast for on computed tomography (CT), gadolinium based agents for MRI and lipid bubble contrast agents used in ultrasound.

News | Contrast Media | November 14, 2018

November 14, 2018 — Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of...

Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018

September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys...

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018

In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore...

Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018

August 24, 2018 — A European research group has developed a system that allows doctors to both improve the accuracy...

Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018

August 22, 2018 — Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to...

Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018

August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...

Videos | Contrast Media | August 03, 2018

Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest...

Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018

July 10, 2018 — Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to...

Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018

March 8, 2018 – Doctors contemplating the best therapy for...

OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.

The global contrast media injectors market is...

TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018

The continuing search for advantages to improve workflow has radiology departments constantly searching for new...

Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018

February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...

A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell

One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs)...

ACR Introduces New Contrast Reaction Card
News | Contrast Media | February 07, 2018

February 7, 2018 — The American College of Radiology (ACR) introduced a new...

Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Approval for Pediatric MRI
News | Contrast Media | January 30, 2018

January 30, 2018 — Bracco Diagnostics Inc. announced the labeling of its...

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop...

Blog | RSNA 2017 | January 18, 2018 | Dave Fornell

The Radiological Association of North America's (RSNA) 2017 conference will be remembered as the year artificial...

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018

January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive...

Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018

January 9, 2018 – Competitive male triathletes face a higher risk of a potentially harmful heart condition called...

Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017

Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of...